Research on antihyperglycemic therapies in patients with type 2 diabetes mellitus in Japan (I): Drug therapies and actual drug use

Journal of the Japan Diabetes Society

Volumn 49, Issue 6, 2006, Pages 409-415

  Kanatsuka, Azuma ^a   Kawai, Koichi ^b   Hirao, Koichi ^c   Oishi, Mariko ^d   Takagi, Hirofumi ^e   Kobayashi, Masashi ^f  

^a Chiba Central Medical Center   (Japan)

^b Kawai Clinic   (Japan)

^c HEC Science Clinic   (Japan)

^d Oishi Clinic   (Japan)

^e NIIGATA UNIVERSITY   (Japan)

^f TOYAMA MEDICAL AND PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALPHA GLUCOSIDASE INHIBITOR; BIGUANIDE; INSULIN; NATEGLINIDE; ORAL ANTIDIABETIC AGENT; SULFONYLUREA;

ADULT; AGED; CONTROLLED STUDY; DRUG USE; FEMALE; HUMAN; INFORMATION PROCESSING; JAPAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RESEARCH; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; REVIEW;

EID: 33746185641     PISSN: 0021437X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (14)

1. Cohen FJ, Conklin JE, Neslusan CA, Song X (2003) Recent antihyperglycemic prescribing trends for U.S. privately insured patients with type 2 diabetes. Diabetes Care 26: 1847-1851
2. UK Prospective Diabetes Study (UKPDS) Group (1998) Effect of Intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 352: 854-864
3. UK Prospective Diabetes Study (UKPDS) Group (1998) Intensive blood-glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352: 837-853
4. Herman LS, Schersten B, Bitzen PO, Kjellstrom T, Lindgarde F, Melander A (1994) Therapeutic comparison of metformin and sulfonylurea, alone and in various combinations. A double-blind controlled study. Diabetes Care 17: 1100-1109
5. Shank M, Del Prato S, Defronzo RA (1995) Bed-time insulin/daytime glipizide. Effective therapy for sulfonylurea failures in NIDDM. Diabetes 44: 165-172
6. Guigliano D, Quatraro A, Consoli G, Minei A, Celliero A, De Rosa N, et al (1993) Metformin for obese, insulin-treated diabetic patients: improvement in glycemic control and reduction of metabolic risk factors. Eur J Clin Pharmacol 44: 107-112
7. Kanatsuka A, Kobayashi M: The relation between the phenotypes and the efficacy of drug(s) in type 2 diabetic patients (2004) CoDiC-based analyses on the clinical data obtained at multiple institutions. Diabetologia 47: Supplement 1, A358
8. Lindholm A, McEwen J, Riis AP (1999) Improved post-prandial glycemic control with insulin aspart. Diabetes Care 22: 801-805
9. Ciszak E, Beals JM, Frank BH, Baker JC, Carter ND, Smith GD (1995) Role of C-terminal β-chain residues in insulin assembly: the structure of hexameric LysB28 ProB29 human insulin. Structure 3: 615-622
10. Hermansen K, Fontaine P, Kukolja KK, Peterkova V, Leth G, Gall MA (2004) Insulin analogues (insulin detemir and insulin aspart) versus traditional human insulins (NPH insulin and regular insulin) in basal-bolus therapy for patients with Type 1 diabetes. Diabetologia 47: 622-629
11. Hermansen K, Colombo M, Storgaard H, Ostergaard A, Kolendorf K, Madsbad S (2002) Improved postprandial glycaemic control with biphasic insulin aspart relative to biphasic insulin lispro and biphasic human insulin in patients with type 2 diabetes. Diabetes Care 25: 883-888